4.1 Review

The importance of integrating medication adherence into pharmacoeconomic analyses: the example of osteoporosis

出版社

TAYLOR & FRANCIS LTD
DOI: 10.1586/ERP.12.8

关键词

adherence; compliance; cost-effectiveness; economic; osteoporosis; persistence

资金

  1. Amgen
  2. Novartis
  3. Servier
  4. Pfizer
  5. Abbott Pharma
  6. Negma
  7. Lilly
  8. Wyeth
  9. GlaxoSmithKline
  10. Roche
  11. Merckle
  12. Nycomed
  13. NPS
  14. Theramex
  15. UCB
  16. Merck Sharp
  17. Rottapharm
  18. IBSA
  19. Genevrier
  20. Teijin
  21. Teva
  22. Ebewee Pharma
  23. Zodiac
  24. Analis
  25. Novo Nordisk
  26. Bristol Myers Squibb
  27. Dohme

向作者/读者索取更多资源

Adherence to medications is poor and suboptimal in many chronic diseases. Nonadherence can reduce treatment effectiveness and can have an impact on healthcare costs. As a consequence, it may alter the cost effectiveness of drug therapies. This article emphasizes the importance of integrating medication compliance and persistence into pharmacoeconomic evaluations, using osteoporosis as an example. A limited number of studies carried out to date have suggested important economic implications of poor adherence to osteoporosis medications. Therefore, compliance and persistence should be an integral part of clinical studies and pharmacoeconomic analyses in order to estimate the cost effectiveness of drug therapies in current community practice. Measuring adherence and incorporating it into health economic modeling may, however, pose particular challenges.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据